NuVasive, Inc. (NUVA)

NASDAQ: NUVA · IEX Real-Time Price · USD
53.03
-0.07 (-0.13%)
May 20, 2022 4:00 PM EDT - Market closed
Market Cap2.76B
Revenue (ttm)1.16B
Net Income (ttm)-37.38M
Shares Out52.04M
EPS (ttm)-0.72
PE Ration/a
Forward PE25.51
Dividendn/a
Ex-Dividend Daten/a
Volume433,434
Open53.56
Previous Close53.10
Day's Range51.78 - 53.90
52-Week Range45.45 - 71.14
Beta1.12
AnalystsBuy
Price Target66.81 (+26.0%)
Earnings DateMay 4, 2022

About NUVA

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that faci...

IndustryHealth Care Equipment & Supplies
Founded1997
CEOJ. Christopher Barry
Employees2,900
Stock ExchangeNASDAQ
Ticker SymbolNUVA
Full Company Profile

Financial Performance

In 2021, NuVasive's revenue was $1.14 billion, an increase of 8.41% compared to the previous year's $1.05 billion. Losses were -$64.09 million, 72.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for NUVA stock is "Buy." The 12-month stock price forecast is 66.81, which is an increase of 25.99% from the latest price.

Price Target
$66.81
(25.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NuVasive (NUVA) Q1 Earnings Beat Estimates, 2022 View Up

Robust sales performance across all U.S. product lines drove NuVasive's (NUVA) Q1 top line.

2 weeks ago - Zacks Investment Research

NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 42.11% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

NuVasive Announces First Quarter 2022 Financial Results

–  Strong year-over-year net sales growth, driven by new product introductions and International sales ––  Company raises lower end of full-year 2022 financial guidance range – SAN DIEGO , May 4, 2022 /...

2 weeks ago - PRNewsWire

MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA

MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.

Other symbols:CRLIDXX
2 weeks ago - Zacks Investment Research

NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

NuVasive Specialized Orthopedics Surpasses 100 Peer-Reviewed Publications of the Precice System for Limb Lengthening

SAN DIEGO , April 26, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) today announced a milestone of more than 100 peer-reviewed publications of the Precice® System (Precice) for conditions related t...

3 weeks ago - PRNewsWire

NuVasive Simplify Cervical Disc Two-level Data Published in Journal of Neurosurgery: Spine

Peer-reviewed results from the two-level multi-center FDA Investigational Device Exemption study reiterate disc's superiority to ACDF SAN DIEGO , April 21, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: N...

1 month ago - PRNewsWire

NuVasive Announces Conference Call and Webcast of First Quarter 2022 Results

SAN DIEGO , April 20, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integra...

1 month ago - PRNewsWire

Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus

Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.

Other symbols:OFIXSYK
1 month ago - Zacks Investment Research

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

Investors are optimistic about NuVasive's (NUVA) better-than-expected revenues and strong spine market presence.

1 month ago - Zacks Investment Research

Why Is NuVasive (NUVA) Down 2.2% Since Last Earnings Report?

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up

Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.

2 months ago - Zacks Investment Research

NuVasive (NUVA) Q4 Earnings Lag Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -14.89% and 1.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

NuVasive Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Outlook

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrate...

2 months ago - PRNewsWire

NuVasive to Participate in 42nd Annual Cowen Healthcare Conference

SAN DIEGO , Feb. 22, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrat...

2 months ago - PRNewsWire

NuVasive Announces Conference Call and Webcast of Fourth Quarter and Full Year 2021 Results

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated...

3 months ago - PRNewsWire

NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer

SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrate...

3 months ago - PRNewsWire

NuVasive (NUVA) Gets FDA Nod for Attrax Putty Expanded Use

NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.

4 months ago - Zacks Investment Research

NuVasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Company's Thoracolumbar Interbo...

SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated...

4 months ago - PRNewsWire

NuVasive to Participate in 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Dec. 28, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrat...

4 months ago - PRNewsWire

NuVasive to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrate...

6 months ago - PRNewsWire

NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical

NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.

Other symbols:GMED
6 months ago - Zacks Investment Research

NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down

NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.

6 months ago - Zacks Investment Research

NuVasive's Q3 Earnings Hit By COVID-19, Staff Shortage; Cuts FY21 Guidance

NuVasive Inc (NASDAQ: NUVA) reported Q3 net sales of $270.8 million, an 8.3% decrease on a reported and constant currency basis, missing the consensus of $291.79 million. "The third quarter presented un...

6 months ago - Benzinga

NuVasive (NUVA) Misses Q3 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -40.74% and -7.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research